Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Fort Lee, NJ, US. The stock last traded at $20.22, down 6.52% on the session, giving a market capitalisation of $536.6M. On trailing twelve-month figures it carries a trailing P/E of -15.44, a net margin of 0.0%. Its beta of -0.26 implies it has historically moved less than the broad market.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Nuvectis Pharma, Inc. is most often compared with the following Healthcare names: